Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
149.4 USD | +1.28% |
|
+3.67% | +11.92% |
09/07 | RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating | MT |
03/07 | ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... | ![]() |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.92% | 14.84B | |
+20.63% | 127B | |
+23.21% | 117B | |
+25.65% | 27.67B | |
-20.17% | 20.33B | |
-16.40% | 16.79B | |
-18.07% | 15.63B | |
-47.70% | 14.65B | |
+58.32% | 14.43B | |
+149.98% | 12.49B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Transcript : Neurocrine Biosciences, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 11